Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zynex ( (ZYXI) ) has shared an update.
On October 7, 2025, Zynex, Inc. expanded its Board of Directors from five to six members by appointing Bret W. Wise, a seasoned executive with extensive experience in the medical device sector, as a director. Mr. Wise will also serve as Chair of the Audit Committee and participate in the Compensation and Nominating and Governance Committees. His appointment is expected to enhance Zynex’s governance and strategic oversight. Additionally, Thomas Sandgaard, who retired as CEO on August 18, 2025, continues to serve as Chair of the Board and Technology Committee, while Anna Lucsok resigned as Chief Commercial Officer, effective October 10, 2025.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
Spark’s Take on ZYXI Stock
According to Spark, TipRanks’ AI Analyst, ZYXI is a Neutral.
Zynex’s overall stock score is primarily impacted by its financial struggles, including declining revenues and profitability, and increased leverage. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. While the earnings call provides some hope with cost reduction and strategic refocus, these efforts are overshadowed by the current challenges.
To see Spark’s full report on ZYXI stock, click here.
More about Zynex
Zynex, Inc. operates in the medical device industry, focusing on providing innovative medical technology solutions.
Average Trading Volume: 235,265
Technical Sentiment Signal: Sell
Current Market Cap: $41.81M
For detailed information about ZYXI stock, go to TipRanks’ Stock Analysis page.